Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

The use of diabetes and weight-loss medications like Ozempic or Wegovy—called GLP-1 drugs—has exploded in recent years, with ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...

Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...

Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...

A new study supports the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

The two drugs are metformin, one of the most widely used diabetes medications, and the GLP-1 class of medications that ...

Mohammad Ali Sheffeh, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief ...

华东医药另一个获批临床试验的产品DR10624注射液为道尔生物自主研发的一款长效三靶点激动剂，适应症为代谢相关脂肪性肝病/代谢相关脂肪性肝炎。截至目前全球尚无同时靶向FGF21R、GLP-1R和GCGR的长效三靶点激动剂药物上市，DR10624注射液具有“first-in-class”潜力。

11月17日，诺和诺德宣布其用于长期体重管理的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂司美格鲁肽（商品名：诺和盈）正式在中国上市，为中国超重和肥胖症患者提供减重选择。